CONMED CORP (CNMD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CNMD - US2074101013 - Common Stock
41.58 USD
+1.55 (+3.87%)
41.58 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to CNMD. CNMD was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While CNMD has a great profitability rating, there are some minor concerns on its financial health. CNMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
- CNMD had positive earnings in the past year.
- In the past year CNMD had a positive cash flow from operations.
- CNMD had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years CNMD had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 2.77%, CNMD is doing good in the industry, outperforming 76.22% of the companies in the same industry.
- CNMD has a better Return On Equity (6.38%) than 79.46% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 5.39%, CNMD is in the better half of the industry, outperforming 77.30% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for CNMD is below the industry average of 8.84%.
- The last Return On Invested Capital (5.39%) for CNMD is above the 3 year average (5.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.77% | ||
| ROE | 6.38% | ||
| ROIC | 5.39% |
ROA(3y)1.68%
ROA(5y)1.82%
ROE(3y)3.56%
ROE(5y)3.99%
ROIC(3y)5.34%
ROIC(5y)4.97%
1.3 Margins
- CNMD has a better Profit Margin (4.77%) than 76.76% of its industry peers.
- CNMD's Profit Margin has improved in the last couple of years.
- With a decent Operating Margin value of 9.99%, CNMD is doing good in the industry, outperforming 78.38% of the companies in the same industry.
- CNMD's Operating Margin has improved in the last couple of years.
- The Gross Margin of CNMD (54.22%) is comparable to the rest of the industry.
- CNMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.99% | ||
| PM (TTM) | 4.77% | ||
| GM | 54.22% |
OM growth 3Y13.68%
OM growth 5Y9.55%
PM growth 3Y17.89%
PM growth 5Y27.61%
GM growth 3Y-0.07%
GM growth 5Y0.25%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CNMD is destroying value.
- CNMD has more shares outstanding than it did 1 year ago.
- CNMD has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for CNMD has been reduced compared to a year ago.
2.2 Solvency
- CNMD has an Altman-Z score of 1.86. This is not the best score and indicates that CNMD is in the grey zone with still only limited risk for bankruptcy at the moment.
- CNMD has a Altman-Z score (1.86) which is comparable to the rest of the industry.
- The Debt to FCF ratio of CNMD is 5.74, which is a neutral value as it means it would take CNMD, 5.74 years of fcf income to pay off all of its debts.
- CNMD has a better Debt to FCF ratio (5.74) than 78.38% of its industry peers.
- CNMD has a Debt/Equity ratio of 0.85. This is a neutral value indicating CNMD is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.85, CNMD is doing worse than 72.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 1.86 |
ROIC/WACC0.61
WACC8.89%
2.3 Liquidity
- A Current Ratio of 2.10 indicates that CNMD has no problem at all paying its short term obligations.
- CNMD's Current ratio of 2.10 is in line compared to the rest of the industry. CNMD outperforms 40.54% of its industry peers.
- CNMD has a Quick Ratio of 2.10. This is a bad value and indicates that CNMD is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of CNMD (0.95) is worse than 78.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.1 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
- CNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.49%, which is quite good.
- The Earnings Per Share has been growing by 9.44% on average over the past years. This is quite good.
- Looking at the last year, CNMD shows a small growth in Revenue. The Revenue has grown by 4.61% in the last year.
- The Revenue has been growing slightly by 6.47% on average over the past years.
EPS 1Y (TTM)16.49%
EPS 3Y9.03%
EPS 5Y9.44%
EPS Q2Q%2.86%
Revenue 1Y (TTM)4.61%
Revenue growth 3Y8.95%
Revenue growth 5Y6.47%
Sales Q2Q%6.7%
3.2 Future
- CNMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.44% yearly.
- Based on estimates for the next years, CNMD will show a small growth in Revenue. The Revenue will grow by 5.19% on average per year.
EPS Next Y10.38%
EPS Next 2Y4.62%
EPS Next 3Y6.36%
EPS Next 5Y9.44%
Revenue Next Year5.12%
Revenue Next 2Y2.86%
Revenue Next 3Y3.63%
Revenue Next 5Y5.19%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 9.20, the valuation of CNMD can be described as very reasonable.
- CNMD's Price/Earnings ratio is rather cheap when compared to the industry. CNMD is cheaper than 95.14% of the companies in the same industry.
- When comparing the Price/Earnings ratio of CNMD to the average of the S&P500 Index (27.33), we can say CNMD is valued rather cheaply.
- CNMD is valuated reasonably with a Price/Forward Earnings ratio of 9.13.
- Based on the Price/Forward Earnings ratio, CNMD is valued cheaper than 95.68% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.12. CNMD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.2 | ||
| Fwd PE | 9.13 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CNMD indicates a rather cheap valuation: CNMD is cheaper than 91.35% of the companies listed in the same industry.
- 98.38% of the companies in the same industry are more expensive than CNMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.66 | ||
| EV/EBITDA | 9.84 |
4.3 Compensation for Growth
- CNMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of CNMD may justify a higher PE ratio.
PEG (NY)0.89
PEG (5Y)0.97
EPS Next 2Y4.62%
EPS Next 3Y6.36%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.81%, CNMD has a reasonable but not impressive dividend return.
- CNMD's Dividend Yield is rather good when compared to the industry average which is at 0.19. CNMD pays more dividend than 95.68% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.91, CNMD has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
- The dividend of CNMD decreases each year by -0.01%.
- CNMD has paid a dividend for at least 10 years, which is a reliable track record.
- CNMD has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.01%
Div Incr Years0
Div Non Decr Years12
5.3 Sustainability
- CNMD pays out 39.73% of its income as dividend. This is a sustainable payout ratio.
DP39.73%
EPS Next 2Y4.62%
EPS Next 3Y6.36%
41.58
+1.55 (+3.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)01-28 2026-01-28/amc
Inst Owners114.3%
Inst Owner Change-0.17%
Ins Owners0.29%
Ins Owner Change0.35%
Market Cap1.29B
Revenue(TTM)1.35B
Net Income(TTM)64.32M
Analysts73.33
Price Target49.37 (18.73%)
Short Float %7.67%
Short Ratio4.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend0.8
Dividend Growth(5Y)-0.01%
DP39.73%
Div Incr Years0
Div Non Decr Years12
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.52%
Min EPS beat(2)0.37%
Max EPS beat(2)0.66%
EPS beat(4)4
Avg EPS beat(4)6.26%
Min EPS beat(4)0.37%
Max EPS beat(4)14.78%
EPS beat(8)7
Avg EPS beat(8)4.08%
EPS beat(12)10
Avg EPS beat(12)-0.4%
EPS beat(16)13
Avg EPS beat(16)0.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.89%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)-0.75%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)0.51%
Revenue beat(8)1
Avg Revenue beat(8)-1.24%
Revenue beat(12)3
Avg Revenue beat(12)-1.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.61%
PT rev (1m)-10.37%
PT rev (3m)-21.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.42%
EPS NY rev (1m)0%
EPS NY rev (3m)0.73%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.2 | ||
| Fwd PE | 9.13 | ||
| P/S | 0.96 | ||
| P/FCF | 8.66 | ||
| P/OCF | 7.69 | ||
| P/B | 1.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.84 |
EPS(TTM)4.52
EY10.87%
EPS(NY)4.55
Fwd EY10.95%
FCF(TTM)4.8
FCFY11.55%
OCF(TTM)5.4
OCFY13%
SpS43.51
BVpS32.56
TBVpS-12.65
PEG (NY)0.89
PEG (5Y)0.97
Graham Number57.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.77% | ||
| ROE | 6.38% | ||
| ROCE | 6.7% | ||
| ROIC | 5.39% | ||
| ROICexc | 5.5% | ||
| ROICexgc | 19.04% | ||
| OM | 9.99% | ||
| PM (TTM) | 4.77% | ||
| GM | 54.22% | ||
| FCFM | 11.04% |
ROA(3y)1.68%
ROA(5y)1.82%
ROE(3y)3.56%
ROE(5y)3.99%
ROIC(3y)5.34%
ROIC(5y)4.97%
ROICexc(3y)5.41%
ROICexc(5y)5.04%
ROICexgc(3y)20.03%
ROICexgc(5y)18.26%
ROCE(3y)6.64%
ROCE(5y)6.18%
ROICexgc growth 3Y14.62%
ROICexgc growth 5Y8.81%
ROICexc growth 3Y13.67%
ROICexc growth 5Y10.96%
OM growth 3Y13.68%
OM growth 5Y9.55%
PM growth 3Y17.89%
PM growth 5Y27.61%
GM growth 3Y-0.07%
GM growth 5Y0.25%
F-Score5
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 5.74 | ||
| Debt/EBITDA | 4.09 | ||
| Cap/Depr | 25.13% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.15% | ||
| Profit Quality | 231.2% | ||
| Current Ratio | 2.1 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | 1.86 |
F-Score5
WACC8.89%
ROIC/WACC0.61
Cap/Depr(3y)25.34%
Cap/Depr(5y)23%
Cap/Sales(3y)1.54%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.49%
EPS 3Y9.03%
EPS 5Y9.44%
EPS Q2Q%2.86%
EPS Next Y10.38%
EPS Next 2Y4.62%
EPS Next 3Y6.36%
EPS Next 5Y9.44%
Revenue 1Y (TTM)4.61%
Revenue growth 3Y8.95%
Revenue growth 5Y6.47%
Sales Q2Q%6.7%
Revenue Next Year5.12%
Revenue Next 2Y2.86%
Revenue Next 3Y3.63%
Revenue Next 5Y5.19%
EBIT growth 1Y-35.26%
EBIT growth 3Y23.86%
EBIT growth 5Y16.64%
EBIT Next Year42.06%
EBIT Next 3Y15.06%
EBIT Next 5YN/A
FCF growth 1Y296.53%
FCF growth 3Y16.67%
FCF growth 5Y15.46%
OCF growth 1Y191.56%
OCF growth 3Y14.3%
OCF growth 5Y11.92%
CONMED CORP / CNMD FAQ
What is the ChartMill fundamental rating of CONMED CORP (CNMD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNMD.
Can you provide the valuation status for CONMED CORP?
ChartMill assigns a valuation rating of 8 / 10 to CONMED CORP (CNMD). This can be considered as Undervalued.
How profitable is CONMED CORP (CNMD) stock?
CONMED CORP (CNMD) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for CNMD stock?
The Price/Earnings (PE) ratio for CONMED CORP (CNMD) is 9.2 and the Price/Book (PB) ratio is 1.28.
What is the expected EPS growth for CONMED CORP (CNMD) stock?
The Earnings per Share (EPS) of CONMED CORP (CNMD) is expected to grow by 10.38% in the next year.